請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42500完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 黃德富 | |
| dc.contributor.author | Yin-Hsuan Chen | en |
| dc.contributor.author | 陳穎萱 | zh_TW |
| dc.date.accessioned | 2021-06-15T01:14:57Z | - |
| dc.date.available | 2011-09-15 | |
| dc.date.copyright | 2009-09-15 | |
| dc.date.issued | 2009 | |
| dc.date.submitted | 2009-07-28 | |
| dc.identifier.citation | Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, Semenza GL.
2001. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61(7):2911-2916. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1(10):1024-1028. Arakaki N, Toyofuku A, Emoto Y, Nagao T, Kuramoto Y, Shibata H, Higuti T. 2004. Induction of G1 cell cycle arrest in human umbilical vein endothelial cells by flavone's inhibition of the extracellular signal regulated kinase cascade. Biochem Cell Biol 82(5):583-588. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. 1999. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 19(5B):4203-4214. Brunton VG, Frame MC. 2008. Src and focal adhesion kinase as therapeutic targets in cancer. Curr Opin Pharmacol 8(4):427-432. Carmeliet P. 2005. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3:4-10. Carmeliet P, Jain RK. 2000. Angiogenesis in cancer and other diseases. Nature 407(6801):249-257. Cherrington JM, Strawn LM, Shawver LK. 2000. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res 79:1-38. Courtneidge SA, Fumagalli S, Koegl M, Superti-Furga G, Twamley-Stein GM. 1993. The Src family of protein tyrosine kinases: regulation and functions. Dev Suppl:57-64. Dai T, Zheng H, Fu GS. 2008. Hypoxia confers protection against apoptosis via the PI3K/Akt pathway in endothelial progenitor cells. Acta Pharmacol Sin 29(12):1425-1431. Dvorak HF, Brown LF, Detmar M, Dvorak AM. 1995. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146(5):1029-1039. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. 1999. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4(6):915-924. Fairbrother WJ, Christinger HW, Cochran AG, Fuh G, Keenan CJ, Quan C, Shriver SK, Tom JY, Wells JA, Cunningham BC. 1998. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry 37(51):17754-17764. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. 1999. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59(16):3915-3918. Ferrara N. 2001. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280(6):C1358-1366. Ferrara N, Davis-Smyth T. 1997. The biology of vascular endothelial growth factor. Endocr Rev 18(1):4-25. Ferrara N, Henzel WJ. 1989. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161(2):851-858. Fidler IJ, Ellis LM. 1994. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79(2):185-188. Folkman J. 1971. Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182-1186. Fong GH, Rossant J, Gertsenstein M, Breitman ML. 1995. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376(6535):66-70. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16(9):4604-4613. Fu Y, Hsieh TC, Guo J, Kunicki J, Lee MY, Darzynkiewicz Z, Wu JM. 2004. Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells. Biochem Biophys Res Commun 322(1):263-270. Fujio Y, Walsh K. 1999. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem 274(23):16349-16354. Fukai N, Eklund L, Marneros AG, Oh SP, Keene DR, Tamarkin L, Niemela M, Ilves M, Li E, Pihlajaniemi T, Olsen BR. 2002. Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 21(7):1535-1544. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V, Ferrara N. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273(46):30336-30343. Gupta K, Zhang J. 2005. Angiogenesis: a curse or cure? Postgrad Med J 81(954):236-242. Gupta MK, Qin RY. 2003. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 9(6):1144-1155. Hanahan D, Folkman J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364. Hanford HA, Wong CA, Kassan H, Cundiff DL, Chandel N, Underwood S, Mitchell CA, Soff GA. 2003. Angiostatin(4.5)-mediated apoptosis of vascular endothelial cells. Cancer Res 63(14):4275-4280. Hockel M, Vaupel P. 2001. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93(4):266-276. Holmqvist K, Cross MJ, Rolny C, Hagerkvist R, Rahimi N, Matsumoto T, Claesson-Welsh L, Welsh M. 2004. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 279(21):22267-22275. Horvathova K, Vachalkova A, Novotny L. 2001. Flavonoids as chemoprotective agents in civilization diseases. Neoplasma 48(6):435-441. Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL. 1998. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12(2):149-162. Jaffe EA, Nachman RL, Becker CG, Minick CR. 1973. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52(11):2745-2756. Karkkainen MJ, Petrova TV. 2000. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19(49):5598-5605. Khwaja A. 1999. Akt is more than just a Bad kinase. Nature 401(6748):33-34. Kinney CM, Chandrasekharan UM, Mavrakis L, DiCorleto PE. 2008. VEGF and thrombin induce MKP-1 through distinct signaling pathways: role for MKP-1 in endothelial cell migration. Am J Physiol Cell Physiol 294(1):C241-250. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. 2000. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105(8):R15-24. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. 1988. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 107(4):1589-1598. Le Marchand L. 2002. Cancer preventive effects of flavonoids--a review. Biomed Pharmacother 56(6):296-301. Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA. 1993. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 121(1):163-170. Li Y, Fang H, Xu W. 2007. Recent advance in the research of flavonoids as anticancer agents. Mini Rev Med Chem 7(7):663-678. Liekens S, De Clercq E, Neyts J. 2001. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 61(3):253-270. Lin P, Sankar S, Shan S, Dewhirst MW, Polverini PJ, Quinn TQ, Peters KG. 1998. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 9(1):49-58. Liotta LA, Steeg PS, Stetler-Stevenson WG. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64(2):327-336. Margolin K, Gordon MS, Holmgren E, Gaudreault J, NovotnyW, Fyfe G, Adelman D, Stalter S, Breed J. 2001. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 19(3):851-856. Mazure NM, Brahimi-Horn MC, Pouyssegur J. 2003. Protein kinases and the hypoxia-inducible factor-1, two switches in angiogenesis. Curr Pharm Des 9(7):531-541. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM. 2000. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 15(1):29-41. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W, Ullrich A. 1993. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72(6):835-846. Moreira IS, Fernandes PA, Ramos MJ. 2007. Vascular endothelial growth factor (VEGF) inhibition--a critical review. Anticancer Agents Med Chem 7(2):223-245. Mukhopadhyay D, Nagy JA, Manseau EJ, Dvorak HF. 1998. Vascular permeability factor/vascular endothelial growth factor-mediated signaling in mouse mesentery vascular endothelium. Cancer Res 58(6):1278-1284. Nicosia RF, Ottinetti A. 1990. Modulation of microvascular growth and morphogenesis by reconstituted basement membrane gel in three-dimensional cultures of rat aorta: a comparative study of angiogenesis in matrigel, collagen, fibrin, and plasma clot. In Vitro Cell Dev Biol 26(2):119-128. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79(2):315-328. Pandya NM, Dhalla NS, Santani DD. 2006. Angiogenesis--a new target for future therapy. Vascul Pharmacol 44(5):265-274. Pedram A, Razandi M, Levin ER. 1998. Extracellular signal-regulated protein kinase/Jun kinase cross-talk underlies vascular endothelial cell growth factor-induced endothelial cell proliferation. J Biol Chem 273(41):26722-26728. Pouyssegur J, Dayan F, Mazure NM. 2006. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441(7092):437-443. Ribatti D. 2005. The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review. Br J Haematol 128(3):303-309. Ribatti D, Vacca A, Presta M. 2000. The discovery of angiogenic factors: a historical review. Gen Pharmacol 35(5):227-231. Rosen LS. 2002. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 9(2 Suppl):36-44. Scappaticci FA. 2002. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20(18):3906-3927. Sebolt-Leopold JS, Herrera R. 2004. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4(12):937-947. Semenza GL. 2003. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721-732. Shibuya M. 2006. Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39(5):469-478. Shibuya M, Claesson-Welsh L. 2006. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312(5):549-560. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M. 1984. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223(4642):1296-1299. Shinkaruk S, Bayle M, Lain G, Deleris G. 2003. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 3(2):95-117. Shukla S, Gupta S. 2004. Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol Carcinog 39(2):114-126. Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, Stolar C, Middlesworth W, Yamashiro DJ, Kandel JJ. 2001. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 36(8):1177-1181. Takahashi H, Shibuya M. 2005. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109(3):227-241. Unruh A, Ressel A, Mohamed HG, Johnson RS, Nadrowitz R, Richter E, Katschinski DM, Wenger RH. 2003. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22(21):3213-3220. Wang GL, Jiang BH, Rue EA, Semenza GL. 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92(12):5510-5514. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF. 2000. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60(4):970-975. Wenzel U, Kuntz S, Brendel MD, Daniel H. 2000. Dietary flavone is a potent apoptosis inducer in human colon carcinoma cells. Cancer Res 60(14):3823-3831. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42500 | - |
| dc.description.abstract | 血管新生(angiogenesis) 是一連串複雜的過程從既有的血管衍生出新生的微血管，其可供給腫瘤細胞所需的養分與氧氣，並且利於癌細胞沿著新生的血管爬行轉移至其他部位。於血管新生的進程當中，內皮細胞會進行增生、爬行、分化的作用，最終形成成熟的血管。抗血管新生的藥物可以減少腫瘤內部新生的血管以及限制腫瘤生長的大小，因此可當作一個治療癌症的新方針。我們以MTT assay 篩選了一系列flavonoids 的衍生物對人類臍帶靜脈內皮細胞(HUVECs) 存活率的影響，最後選擇效果較佳的fla-2 來繼續研究探討其抗血管新生作用與相關機轉。
Fla-2 會抑制內皮細胞的增生，且此抑制作用呈現劑量相關性，進一步的研究中發現fla-2 會增加細胞週期中sub-G1 相的分佈，顯示出fla-2 可能是藉由引發內皮細胞凋亡(apoptosis) 來抑制其增生的現象。Fla-2 可依劑量相關性顯著的抑制內皮生長因子(VEGF) 所誘發之內皮細胞移行現象。Fla-2 會抑制內皮細胞經由內皮生長因子所刺激的管狀生成，且於60 μM 即可完全抑制內皮生長因子的作用。內皮生長因子引誘內皮細胞從大鼠主動脈血管環中爬行出來並形成管狀結構的作用也會被fla-2 隨著劑量的增高而完全抑制。另一方面，fla-2 對內皮生長因子及其接受器結合所活化之訊息傳遞分子(Akt, ERK, JNK—MAPK) 也具有劑量相關性的抑制作用。除此之外，內皮細胞因為處於缺氧的環境下所產生的轉錄因子HIF-1α及其上游之訊息傳遞分子Akt 的活化也可被fla-2 所抑制。 總結來說，fla-2 藉由引起內皮細胞凋亡，抑制內皮生長因子所誘發之內皮細胞移行、管狀生成及其相關之訊息傳遞等作用來展現出fla-2 具有良好的抗血管新生能力，未來可依此方向發展成一嶄新的抗血管新生藥物。 | zh_TW |
| dc.description.abstract | Angiogenesis contributes to the progression of tumor and metastasis by forming new capillaries from the pre-existing blood vessels. Endothelial cells play an important role in the processes of angiogenesis including cell proliferation, migration, differentiation and tube formation. Anti-angiogenic agents reduce the tumor vasculature and growth, thereby being a therapeutic strategy for cancer. We
investigated the action of fla-2, a synthetic flavonoids derivative compound, on human umbilical vein endothelial cells (HUVECs). Fla-2 inhibited HUVEC viability and proliferation in a concentration-dependent manner as measured by MTT assay and BrdU proliferation assay, respectively. Fla-2 inhibited cell proliferation by inducing cell apoptosis as evidenced by the increased sub-G1 phase examined by PI staining using flow cytometry. VEGF-induced cell migration and tube formation were concentration-dependently inhibited by fla-2. Moreover, fla-2 also inhibited endothelial cells sprouting from aortic ring stimulated by VEGF. Besides, fla-2 blocked the activation of Akt, ERK, JNK—MAPK stimulated by VEGF treatment. It also inhibited HIF-1α expression and Akt phosphorylation of endothelial cells induced by hypoxia in a concentration-dependent manner. In conclusion, fla-2 exhibited anti-angiogenic activity by inducing endothelial cell apoptosis and inhibiting cell migration, tube formation, and signaling involved in VEGF-VEGFR pathway. These results suggest that fla-2 could be a potential compound for developing as a anti-angiogenic agents. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T01:14:57Z (GMT). No. of bitstreams: 1 ntu-98-R96443017-1.pdf: 2071493 bytes, checksum: 2038010233d65206b541a7058a61d235 (MD5) Previous issue date: 2009 | en |
| dc.description.tableofcontents | 目錄
口試委員會審定書…………………………………………………… i 中文摘要…………………………………………………………… ii 英文摘要…………………………………………………………… iv 縮寫表………………………………………………………………… vi 第一章Introduction………………………………………………… 1 1.1 Angiogenesis………………………………………………… 1 1.2 Angiogenesis and cancer…………………………………… 2 1.3 VEGF and receptor…………………………………………… 3 1.4 Signal transduction induced by VEGF……………………… 4 1.5 Hypoxia and HIF-1…………………………………………… 5 1.6 Fla-2…………………………………………………………… 6 第二章Materials and methods……………………………………… 18 第三章Results……………………………………………………… 25 3.1 Fla-2 inhibited endothelial cell viability and proliferation…… 25 3.2 Fla-2 caused cell cycle arrest and apoptosis………………… 25 3.3 Effect of fla-2 on VEGF-induced endothelial cells migration…26 3.4 Fla-2 inhibited VEGF-induced tube formation in vitro……… 27 3.5 Effet of fla-2 on VEGF-induced aortic ring sprouting……… 28 3.6 Effect of fla-2 on VEGF-induced signal transduction……… 28 3.7 Effect of fla-2 on hypoxia-induced activation of HIF-1α and Akt……………………………………………………………… 30 第四章Discussion…………………………………………………… 48 第五章 Conclusion and future work………………………………… 53 Reference……………………………………………………………… 55 | |
| dc.language.iso | en | |
| dc.subject | 人類臍靜脈內皮細胞 | zh_TW |
| dc.subject | 血管新生 | zh_TW |
| dc.subject | 細胞凋亡 | zh_TW |
| dc.subject | 血管內皮增生因子 | zh_TW |
| dc.subject | angiogenesis | en |
| dc.subject | HUVEC | en |
| dc.subject | VEGF | en |
| dc.subject | apoptosis | en |
| dc.title | Fla-2 抑制血管內皮生長因子引發之血管新生作用之探討 | zh_TW |
| dc.title | The inhibitory effects of fla-2 on angiogenesis induced by vascular endothelial growth factor | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 97-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 鄧哲明,顏茂雄,楊春茂 | |
| dc.subject.keyword | 血管新生,細胞凋亡,血管內皮增生因子,人類臍靜脈內皮細胞, | zh_TW |
| dc.subject.keyword | angiogenesis,apoptosis,VEGF,HUVEC, | en |
| dc.relation.page | 66 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2009-07-28 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 藥理學研究所 | zh_TW |
| 顯示於系所單位： | 藥理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-98-1.pdf 未授權公開取用 | 2.02 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。